Loading
companiesCompany
Interius BioTherapeutics
Penn spin-out that dosed the first patient ever with a durable in vivo CAR gene therapy (INT2104, CD20) in the INVISE trial.
Overview
INT2104 is an engineered lentiviral vector that generates CAR-T and CAR-NK cells against CD20 after a single IV infusion, without lymphodepletion. Phase 1 INVISE in relapsed/refractory B-cell malignancies started in Australia (2024-25); preclinical large-animal data showed B-cell depletion without CRS or neurotoxicity.
Similar pages
- CompanyUmoja Biopharma
Shares In vivo CAR-T manufactured and priced like a generic biologic, In vivo CAR-T as a vial on the shelf: a cost and access trial in lymphoma, In vivo CAR-T, Manufacturing cost and time for living and radioactive medicines and the tag frontier.
- CompanyOrna Therapeutics (Eli Lilly)
Shares In vivo CAR-T manufactured and priced like a generic biologic, In vivo CAR-T as a vial on the shelf: a cost and access trial in lymphoma, In vivo CAR-T, Manufacturing cost and time for living and radioactive medicines and the tag frontier.
- TechnologyCAR-NK & CAR-macrophage
Shares Manufacturing cost and time for living and radioactive medicines and the tag frontier.
- TechnologyTargeted alpha therapy
Shares Manufacturing cost and time for living and radioactive medicines and the tag frontier.
- TechnologyIn vivo base and prime editing for cancer
Shares In vivo CAR-T and the tag frontier.
- TechnologySelf-amplifying and circular RNA therapeutics
Shares In vivo CAR-T and the tag frontier.
- TechnologyEngineered exosomes as drug carriers
Shares In vivo CAR-T and the tag frontier.
- TechnologyLogic-gated therapeutics (AND, NOT gates)
Shares In vivo CAR-T and the tag frontier.